 |
|
|
| |
Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ± Ribavirin for 8 or 12 Weeks in Treatment-Naïve Patients with Genotype 1-6 HCV Infection
|
| |
| |
Reported by Jules Levin
AASLD Boston Nov 8-11 2014
Tram T. Tran1, Timothy R. Morgan2 , Paul J. Thuluvath3, Kyle Etzkorn4,
Federico Hinestrosa5, Myron Tong6, John McNally7, Diana M. Brainard7,
Lingling Han7, Brian Doehle7, Erik Mogalian7, John G. McHutchison7,
Raymond T. Chung8, Gregory T. Everson9
1Cedars-Sinai Medical Center, Los Angeles, CA; 2VA Long Beach, Long Beach, CA; 3Mercy Medical Center, Baltimore, MD; 4Borland-Groover Clinic, Jacksonville, FL; 5Orlando Immunology Center, Orlando, FL; 6Huntington Medical Research Institutes, Pasadena, CA; 7Gilead Sciences, Inc., Foster
City, CA; 8Massachusetts General Hospital, Boston, MA; 9University of Colorado Denver, Aurora, CO
|
| |
|
|
|
|
|
